A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

• Published in: SpringerPlus Vol. 2; no. 1; p. 236
• Main Authors: Stott, Colin, White, Linda, Wright, Stephen, Wilbraham, Darren, Guy, Geoffrey
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 24.05.2013; Springer Nature B.V; BioMed Central Ltd; Springer International Publishing AG
• Subjects: Biomedical and Life Sciences; Humanities and Social Sciences; Metabolites; multidisciplinary; Pharmacokinetics; Science; Science (multidisciplinary); Sprays; Delta-9-tetrahydrocannabinol; Cannabidiol; Sativex; Nabiximols; Cytochrome P450; THC/CBD spray

This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex ® , nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole...